A patient may leave a consultation believing they have chosen between a cannabis clinic and a private prescription. In practice, cannabis clinics versus private prescriptions is not a straightforward either-or decision. A private prescription is the legal route by which a clinician authorises a cannabis-based medicinal product. A clinic is the service structure around that prescription: the doctors, assessments, follow-ups, pharmacy arrangements and patient support.
That distinction matters as the UK medical cannabis market expands. Product availability is broader than it was even a few years ago, but access remains private for most patients, NHS prescribing is still limited, and the quality of service can vary considerably between providers. For patients, clinicians, employers and investors watching the sector, the real question is not simply where a prescription comes from. It is whether the route provides appropriate clinical care, reliable supply and a sustainable cost.
What a private cannabis prescription actually means
In the UK, medical cannabis can be prescribed by a doctor on the Specialist Register of the General Medical Council. Most prescriptions are for unlicensed cannabis-based products for medicinal use, commonly referred to as CBPMs. They are prescribed where a specialist considers there is a clinical rationale, often after standard treatments have not delivered adequate benefit or have caused unacceptable side effects.
A private prescription is therefore not a product membership, a consumer subscription or a guarantee that a particular flower, oil or vape cartridge will be available. It is a clinical decision made for an individual patient. The prescription must be issued, dispensed by an appropriate pharmacy and reviewed over time.
A patient may obtain that prescription through a dedicated cannabis clinic, a broader private specialist practice, or in limited cases through an NHS pathway. The prescription itself has the same legal standing when correctly written and dispensed. What differs is the framework surrounding it.
Cannabis clinics versus private prescriptions: the key difference
Dedicated clinics have built their operating model around medical cannabis. They commonly offer an initial eligibility assessment, specialist consultation, repeat prescribing, dosage adjustments and pharmacy coordination. Some also provide patient-facing support teams that can help with appointments, letters for travel and questions about dispensing.
This can be useful for patients with complex needs or little prior experience of prescribed cannabis. A clinic that regularly manages CBPMs may be more familiar with available formulations, changing stock positions, adverse-effect monitoring and the evidence base for particular indications.
But a clinic is not automatically superior merely because it is cannabis-focused. Its value depends on the quality of its medical governance, the experience of its prescribers, the transparency of its charges and whether it allows decisions to be driven by clinical need rather than a narrow commercial arrangement.
A private specialist prescription outside a dedicated clinic can suit patients already under the care of a consultant for pain, neurology, psychiatry or another relevant field. The potential advantage is continuity: the prescriber may understand the patient’s wider history, medicines and treatment goals in greater depth. The limitation is that many private specialists do not prescribe cannabis, may have little experience with it, or may not have established dispensing processes.
In short, a clinic can make access more organised. A private prescription from another specialist can make care more integrated. Neither route removes the need for careful assessment and follow-up.
Cost is more than the price of the medicine
The headline cost of cannabis medicine is only one part of a patient’s financial commitment. Private clinics may charge for an initial appointment, mandatory follow-ups, repeat prescriptions, administrative changes and letters. Product costs then vary by format, prescribed quantity, pharmacy and availability.
Some providers use a low entry price but require regular paid reviews. Others charge more at the outset while including certain prescription services. Neither approach is inherently unfair, but patients should be able to see the likely annual cost before committing. A transparent provider will explain consultation frequency, prescription fees, dispensing arrangements and the consequences of needing to change products because of stock shortages.
Cost also affects adherence. If a patient can only afford a prescription intermittently, it becomes harder for the clinician to assess benefit, side effects and appropriate dosing. This is particularly relevant where a prescribed product is intended to support long-term symptom management rather than short-term relief.
The NHS remains a very different proposition. NHS prescriptions for medical cannabis are uncommon and generally restricted to a small number of licensed products and tightly defined indications. For most people seeking CBPMs in Britain, private care remains the practical route. That creates an access gap which policymakers and patient groups continue to scrutinise.
Product choice should follow the clinical plan
The commercial language around cannabis can make product choice sound like a retail preference. In a medical setting, it should begin with the patient’s symptoms, treatment history, daily routine, risk factors and response to previous therapies.
Oils can offer measured dosing and may be preferred by patients who do not wish to use inhaled products. Dried flower may have a faster onset and is prescribed for some patients, but it requires discussion around administration, odour, public use and practical storage. Other preparations may be available, although supply is not always consistent.
A good clinic or private specialist will explain why a certain formulation is being considered, how to start cautiously and what would justify a change. Patients should be wary of any service that appears to promise a particular strain before a consultation, or treats higher-THC products as an automatic next step.
Availability is also a market issue. Imported products, batch changes and pharmacy logistics can affect continuity. A prescriber with experience of the sector may be able to offer clinically suitable alternatives quickly. That is one of the less visible benefits of a well-run clinic, although it should never become a reason to substitute products without proper patient discussion.
Continuity, safety and the role of the GP
Private cannabis care often sits alongside NHS care rather than replacing it. A patient’s GP may hold important information about diagnoses, blood pressure, mental health history and concurrent medication, while the cannabis prescriber manages the CBPM. However, many GPs are unable or unwilling to enter shared-care arrangements for private cannabis prescriptions. Patients should not assume their GP will prescribe, monitor or fund treatment initiated elsewhere.
Clear communication is essential. The prescribing clinician should know about all medicines and relevant medical history. Patients should also understand the potential for side effects, including sedation, dizziness, anxiety, cognitive changes and interactions with other treatments. Particular care may be needed for people with a personal or family history of psychosis, significant cardiovascular disease, pregnancy or a history of substance-use disorder.
Medical cannabis does not exempt a patient from ordinary safety responsibilities. Driving while impaired remains illegal, even where the medicine is legally prescribed. Employers may also have legitimate concerns for safety-critical roles. A clinic that provides a prescription without addressing driving, work and storage is not offering complete care.
Questions worth asking before choosing a provider
Before enrolling with a clinic or seeking a private specialist, patients should establish who will prescribe, how often reviews are required and what happens if the usual doctor is unavailable. They should ask for a full schedule of fees, including repeat prescriptions and administrative requests.
It is also reasonable to ask whether the provider has any restrictions on pharmacy choice, how it manages stock shortages, and whether there is a clear route to report side effects or seek timely clinical advice. For patients with several conditions or multiple medicines, the more important question may be whether the prescriber will coordinate sensibly with existing clinicians.
For the industry, these questions point to a maturing market. Scale alone will not build trust. The providers most likely to retain patients will be those that combine efficient digital access with credible specialist oversight, price clarity and an approach that treats cannabis as one part of a wider care plan.
The best route is the one that gives a patient enough clinical attention to make informed decisions, without turning necessary treatment into an opaque and expensive administrative process. As private prescribing continues to shape the UK market, that standard should be the baseline, not a premium extra.